araag2/HINT huggingface dataset:
Clinical trial NCT00047008 (phase 3, status: unknown status)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx,
             hypopharynx, or larynx

               -  Stage III or IV (T2, N2-3, M0 or T3-4, any N, M0)

          -  No metastases below the clavicle or more distant by clinical exam or radiology

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute granulocyte count at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 1.5 mg/dL

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) no greater than 2
             times upper limit of normal

        Renal

          -  Creatinine no greater than 1.5 mg/dL

          -  Creatinine clearance at least 50 mL/min

          -  Calcium normal

        Cardiovascular

          -  No symptomatic coronary artery disease (angina)

          -  No myocardial infarction within the past 6 months

        Other

          -  No other invasive malignancy within the past 3 years except nonmelanoma skin cancer

          -  No simultaneous primary tumors

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy to the head and neck except radioactive iodine therapy

        Surgery

          -  No prior surgery to the primary tumor or nodes except diagnostic biopsy or nodal
             sampling of neck disease

               -  No radical or modified neck dissection
Clinical trial NCT00252824 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol turbuhaler vs conventional best asthma therapy
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  - Diagnosis of asthma ³ 3 months

          -  Prescribed daily use of glucocorticosteroids at a dose > 320 mcg/ day for at least 3
             months prior to Visit 1

        Exclusion Criteria:

          -  Smoking history > 10 pack-years

          -  Asthma exacerbation requiring change in asthma treatment during the last 14 days prior
             to inclusion

          -  Any significant disease or disorder that my jeopardize the safety of the patient.

        Additional inclusion and exclusion criteria will be evaluated by the investigator.
Clinical trial NCT00542386 (phase 3, status: completed)
Conditions: chronic kidney disease, dialysis, hyperphosphatemia, dyslipidemia
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: mci-196, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years of age or over

          -  Clinically stable haemodialysis or peritoneal dialysis

          -  Stable phosphate control

          -  On a stabilised phosphorus diet

          -  Female and of child-bearing potential have a negative serum pregnancy test

          -  Male subjects must agree to use appropriate contraception

        Exclusion Criteria:

          -  Current clinically significant medical comorbidities, which may substantially
             compromise subject safety, or expose them to undue risk, or interfere significantly
             with study procedures and which, in the opinion of the Investigator, makes the subject
             unsuitable for inclusion in the study.

          -  A a serum albumin level<30.0g/L

          -  A PTH level >1000pg/mL

          -  A body mass index (BMI)<= 16.0kg/㎡ or =>40.0kg/㎡

          -  A serum LDL-C level >4.94mmol/L(190mg/dL)

          -  A serum triglycerides level >6.76mmol/L (600mg/dL)

          -  A History of significant gastrointestinal motility problems

          -  A positive test for HIV 1 and 2 antibodies

          -  A history of substance or alcohol abuse within the last year

          -  Seizure disorders

          -  A history of drug or other allergy

          -  A temporary catheter as a vascular access

          -  Participated in a clinical study with any experimental medication in the last 30 days
             or an experimental biological product within the last 90 days prior to signing of
             informed consent
Clinical trial NCT00135395 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: atazanavir+ritonavir, lopinavir+ritonavir
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients ≥ 18 years of age infected with HIV

          -  Plasma HIV RNA ≥ 1000 copies/mL and CD4 cell count ≥ 50 cells/mm3

          -  Currently receiving a NNRTI-containing HAART regimen or not currently receiving a
             NNRTI-containing HAART regimen and have not been treated with an alternative regimen
             since the documented virologic failure (with genotype performed within 2 weeks of the
             discontinuation of the failing regimen and the genotype report is available)

          -  The failing NNRTI-containing regimen must be the patient's first virologic failure on
             treatment and contain a NNRTI and at least 2 NRTIs. The regimen must have been
             administered for at least 24 weeks and the patient must have documented virologic
             response to the regimen (HIV RNA < 400 c/mL)

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Reported virologic failure to two or more antiretroviral regimens

          -  Active AIDS-defined opportunistic infection or disease

          -  Proven or suspected acute hepatitis within 30 days prior to study entry
Clinical trial NCT00329147 (phase 3, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: desvenlafaxine sr, desipramine, paroxetine
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy men and women between 18 to 55 years of age

          -  Healthy as determined by the investigator on the basis of medical history and physical
             examination, laboratory test results, vital signs, and 12-lead electrocardiogram (ECG)

          -  History of being a nonsmoker for at least 1 year Other inclusions apply.

        Exclusion Criteria:

          -  Presence or history of any disorder or significant cardiovascular, hepatic, renal,
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, or neurologic
             condition, and any severe conditions of the ears, eyes or throat (such as glaucoma or
             increased intraocular pressure) or psychiatric disease

          -  Known or suspected alcohol abuse or consumption of more than 2 standard units per day
             within the past 6 months

          -  Use of any over-the-counter, prescription, hormonal therapy or investigational
             medications within 30 days of study day-1 until the end of the study Other exclusions
             apply.
Clinical trial NCT00078806 (phase 3, status: terminated)
Conditions: juvenile rheumatoid arthritis
ICD codes: M08.08, M08.48, M08.011, M08.012, M08.019, M08.021, M08.022
Drugs: etanercept, placebo
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated because of slow enrollment
  
Eligibility criteria:

        INCLUSION CRITERIA:

          -  2 - 18 years of age

          -  SOJRA for at least 3 months, with stable systemic features

          -  If taking methotrexate, hydroxychloroquine, or NSAIDs, dose must be stable

          -  Must take prednisone at a stable dose

        EXCLUSION CRITERIA:

          -  Need for other DMARDs or prestudy requirements for oral or parenteral pulse steroids
             or intra-articular steroids

          -  Pregnant or nursing female

          -  Clinically significant abnormal laboratory test results for blood cells, liver or
             kidney function, or serology

          -  Previous receipt of any tumor necrosis factor (TNF) inhibitor

          -  Live virus vaccine within 12 weeks of study entry

          -  Participation in another study requiring informed consent within 12 weeks of entry

          -  Diabetes that requires insulin treatment

          -  Infection, chronic, recurrent, or currently active

          -  Any serious medical or psychiatric condition or history of alcohol or drug abuse
Clinical trial NCT01294436 (phase 3, status: completed)
Conditions: type2 diabetes, high blood sugar
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Men or women age ≥20 years old (Either gender needs to be 40% or higher of total
             number of treated subjects)

          -  diagnosed with type2 DM ; ≥6.5% and ≤10% at 1 week before treatment started

        Exclusion Criteria:

          -  Type 1 diabetes mellitus,

          -  FPG >240 mg/dL before treatment started

          -  Subjects who have history of unstable or rapidly progressing renal disease

          -  Subjects who have severe hepatic insufficiency and/or significant abnormal liver
             function

          -  Significant cardiovascular history
Clinical trial NCT00660504 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: amrubicin hydrochloride, etoposide-cisplatin combined chemotherapy
SMILES: [H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically proven small cell lung cancer

          -  Extensive disease

          -  No prior chemotherapy regimen

          -  Age 18 years or older

          -  ECOG performance status of 0-1

        Exclusion Criteria:

          -  Brain metastasis requiring treatment

          -  Treatment (Surgical or radiotherapy)of primary tumor

          -  Interstitial pneumonia or pulmonary fibrosis

          -  Abnormal cardiac function or myocardial infraction within 6 months before study
             enrollment
Clinical trial NCT01768481 (phase 3, status: completed)
Conditions: obesity, dyslipidemia
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: atorvastatin, sugar pill
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Obesity

          -  Abnormal Triglyceride levels (>1.7mmol/L).

          -  Abnormal HDL-C levels (1.0mmol/L)

        Exclusion Criteria:

          -  Abnormal thyroid unfction (not treated)

          -  Diabetes
Clinical trial NCT00411242 (phase 3, status: completed)
Conditions: major depressive disorder (mdd)
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: agomelatine, placebo
SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder, single or recurrent episode, according to
             DSM-IV criteria

          -  HAM-D17 total score > or = 22 at Screening and Baseline

          -  CGI-Severity score > or = 4 at Screening and Baseline

          -  Only patients who complete the core protocol are eligible to participate in the
             Open-Label Extension Phase

        Exclusion Criteria:

          -  History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating
             disorder, or obsessive compulsive disorder

          -  Any current Axis I disorder other than major depressive disorder which is the focus of
             treatment

          -  Substance or alcohol abuse in the last 30 days, dependence in the last 6 months

          -  Concomitant psychotropic medication, including herbal preparations and melatonin

          -  Psychotherapy of any type

          -  Female patients of childbearing potential who are not using effective contraception

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01566604 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: nva237, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure

          -  With moderate to severe stable COPD (Stage II or Stage III).

          -  Current or ex-smokers who have a smoking history of at least 10 pack years (Ten pack-
             years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20
             years).

          -  Post-bronchodilator FEV1 ≥30% and < 80% of the predicted normal, and
             post-bronchodilator FEV1/FVC < 0.7 at Visit 2 (Day -14) (post means: record FEV1 and
             FVC 45 min after administering ipratropium).

          -  Symptomatic patients, according to daily electronic diary data between Visit 2 (Day
             -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7
             days prior to Visit 3

        Exclusion Criteria:

          -  With a history of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years whether or not there is evidence of local
             recurrence or metastases, with the exception of localized basal cell carcinoma of the
             skin.

          -  Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count > 600/mm3 (at Visit 2) or onset of symptoms prior to age 40 years.
             Patients without asthma but who have a blood eosinophil count >600/mm3 at Visit 2 are
             excluded.

          -  Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless
             confirmed by imaging to be no longer active) or clinically significant bronchiectasis,
             sarcoidosis and interstitial lung disorder.

          -  Patients with lung lobectomy or lung volume reduction or lung transplantation.

          -  Patients with known history and diagnosis of α-1 antitrypsin deficiency.

          -  Patients who have had a COPD exacerbation that required treatment with antibiotics,
             systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to
             Visit 1 Patients who have had a respiratory tract infection within 6 weeks prior to
             Visit 1.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01051011 (phase 3, status: terminated)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine, metformin, taspoglutide, taspoglutide
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
Reason stopped: 
    high discontinuation rates mainly due to gi tolerability and implementation of risk mitigation
    plan to address hypersensitivity reactions
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age

          -  type 2 diabetes mellitus, treated with stable dose of metformin and sulfonylurea for
             >/= 12 weeks prior to screening

          -  HbA1c 7-10% at screening

          -  body weight stable (+/-5%) for >/= 12 weeks prior to screening

          -  fasting C-peptide >/=1ng/ml

          -  treatment-naïve for insulin

        Exclusion Criteria:

          -  diagnosis or history of type 1 diabetes mellitus or secondary forms of diabetes

          -  acute metabolic diabetic complications or evidence of clinically significant diabetic
             complications

          -  clinically symptomatic gastrointestinal disease

          -  history of chronic pancreatitis or acute idiopathic pancreatitis

          -  >3 episodes of severe hypoglycemia within 6 months prior to screening

          -  miocardial infarcion, unstable angina pectoris, coronary artery bypass surgery,
             post-transplantation cardiomyopathy or stroke within 6 months prior to screening

          -  any treatment with exenatide, exendin analogues, GLP-1 or its analogues
Clinical trial NCT00083993 (phase 3, status: terminated)
Conditions: breast neoplasms, neoplasm metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: temsirolimus (cci-779) for 34 months, letrozole for 34 months
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Women aged greater than 18 years.

          -  Postmenopausal subjects

          -  Confirmed diagnosis of locally advanced (not amenable to curative surgery and/or
             radiation) or metastatic breast cancer (Stage 3B or 4 respectively, by American Joint
             Committee on Cancer Criteria)

        Exclusion Criteria:

          -  Extensive visceral disease

          -  Subjects with bone as the only site of disease

          -  Prior radiation therapy to the site of measurable disease for subjects with a solitary
             measurable lesion
Clinical trial NCT00463775 (phase 3, status: withdrawn)
Conditions: alcohol dependence, borderline personality disorder
ICD codes: F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, F10.288, F60.3
Drugs: topiramate
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Reason stopped: 
    recruitment not progressing as planned.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of AD

          -  Diagnosis of BPD

        Exclusion Criteria:

          -  Serious or unstable medical condition

          -  Opiate dependence

          -  Major Axis I disorder (bipolar disorder, schizophrenia)

          -  Taking mood stabilizers and antipsychotic medications

          -  LFT abnormalities that do not exceed 3 times normal values
Clinical trial NCT00613002 (phase 3, status: completed)
Conditions: hypoactive sexual desire disorder
ICD codes: F52.0
Drugs: testosterone gel, placebo gel
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be between the ages of 30 to 65 years

          -  Must have undergone hysterectomy and bilateral salpingo-oophorectomy

        Exclusion Criteria:

          -  A history of allergic reactions to androgens (oral or patch), topical alcohol, or any
             component of the formulation

          -  Any systemic skin diseases or local skin abnormalities in the area of application

          -  Diagnosed with another primary female sexual dysfunction (e.g., Sexual Aversion
             Disorder, Female Sexual Arousal Disorder).

          -  A medical condition that could affect or interfere with sexual function

          -  Using a systemic topical gel or cream estrogen therapy.